Improving lesion detection and visualization: Implications for neurosurgical planning and follow-up

Neuroradiology

Volumn 49, Issue SUPPL. 1, 2007, Pages

  Picozzi, Piero ^a   Kirchin, Miles A ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Bracco Imaging SpA   (Italy)

Author keywords

Contrast agents; MRI; Neurosurgery; Radiosurgery

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; GADOBENATE DIMEGLUMINE; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; PROTEIN;

ASTROCYTOMA; BRAIN RADIATION; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CONTRAST ENHANCEMENT; COST CONTROL; CRANIOPHARYNGIOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG PROTEIN BINDING; EPENDYMOBLASTOMA; EPENDYMOMA; FOLLOW UP; GANGLIONEUROMA; GLIOBLASTOMA; GLIOMA; HEALTH CARE COST; HOSPITALIZATION; HUMAN; IMAGE QUALITY; INTRAOPERATIVE PERIOD; LENGTH OF STAY; MEDULLOBLASTOMA; NEUROPATHOLOGY; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PINEAL BODY TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL DETECTION; SINGLE DRUG DOSE; TREATMENT PLANNING; TUMOR CLASSIFICATION;

BRAIN NEOPLASMS; CONTRAST MEDIA; DECISION MAKING, COMPUTER-ASSISTED; HUMANS; MAGNETIC RESONANCE IMAGING; MEGLUMINE; ORGANOMETALLIC COMPOUNDS;

EID: 34547569670     PISSN: 00283940     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00234-007-1470-4     Document Type: Review

References (84)

1. Central Brain Tumor Registry of the United States (CBTRUS). 2002 tables. Available at: http://www.cbtrus.org/2002tables2002_18.htm (accessed 11 January 2007)
2. National Cancer Institute (2007) Surveillance, Epidemiology, and End Results (SEER) Program Public Use Data (1973-2001). Division of Cancer Control and Population Sciences (DCCPS), Surveillance Research Program, Cancer Statistics Branch, Bethesda, MD
3. Curtis RE, Freedman DM, Ron E et al (2006) New malignancies among cancer survivors: SEER cancer registries, 1973-2000 (NIH publication no. 05-5302). National Cancer Institute, Bethesda, MD
4. Davis FG, Freels S, Grutsch J et al (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histologic subtype: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 88:1-10
5. Davis FG, McCarthy BJ, Freels S et al (1999) The conditional probability of survival of patients with primary malignant brain tumors. Cancer 85:485-491
6. Olson J, Riedel E, DeAngelis LM (2000) Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54:1442-1448
7. Russell DS, Rubenstein LJ (1989) Pathology of tumours of the nervous system, 5th edn. Williams and Wilkins, Baltimore, MD
8. Yates AJ (1992) An overview of principles for classifying brain tumors. Mol Chem Neuropathol 17:103-120
9. Ng HK, Tse CCH, Lo STH (1987) Meningiomas and arachnoid cells: An immunohistochemical study of epithelial markers. Pathology 19:253-257
10. Kepes JJ (1986) Presidential address. The histopathology of meningiomas: a reflection of origins and expected behavior? J Neuropathol Exp Neurol 45:95-107
11. McKinney PA (2004) Brain tumours: Incidence, survival, and aetiology. J Neurol Neurosurg Psychiatry 75[Suppl 2]:iI12-ii17
12. Jacobs AH, Kracht LW, Gossmann A et al (2005) Imaging in neurooncology. J Am Soc Exp Neurother 2:333-347
13. De Angelis LM (2001) Brain tumors. N Engl J Med 344(2):114-123
14. Snyder H, Robinson K, Shah D et al (1993) Signs and symptoms of patients with brain tumors presenting to the emergency department. J Emerg Med 11(3):253-258
15. Grant R (2004) Overview: Brain tumour diagnosis and management. Royal College of Physicians guidelines. J Neurol Neurosurg Psychiatry 75[Suppl 2]:iI18-ii23
16. Inskip PD, Heineman EF (2007) New malignancies following cancer of the brain and central nervous system. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr (eds) New malignancies among cancer survivors: SEER cancer registries, 1973-2000. National Cancer Institute, Bethesda, MD. Available at http://seer.cancer.gov/publications/mpmono/Ch14_Brain.pdf (accessed 11 January 2007)
17. Claus EB, Horlacher A, Hsu L et al (2005) Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer 103:1227-1233
18. Claus EB, Black PM (2006) Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: Data from the SEER Program, 1973-2001. Cancer 106:1358-1363
19. Lassman AB, DeAngelis LM (2003) Brain metastases. Neurol Clin 21(1):1-23
20. Levin VA, Leibel SA, Gutin PH (2001) Neoplasms of the central nervous system. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott Williams & Wilkins, Philadelphia, PA, pp 2100-2160
21. Mahaley MS, Mettlin C, Natarajan N et al (1989) National survey of patterns of care for brain-tumor patients. J Neurosurg 71(6):826-836
22. Surawicz TS, Davis F, Freels S et al (1998) Brain tumor survival: results from the National Cancer Data Base. J Neurooncology 40(2):151-160
23. Kleihues P, Cavanne WK (eds) (2000) Pathology and genetics of tumors of nervous system. World Health Organization classification of tumours. IARC Press, Lyon, France
24. Kleihues P, Louis DN, Scheithauer BW et al (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61(3):215-225
25. Royal College of Radiologists (2006) Recommendations for cross-sectional imaging in cancer management: Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET-CT) (ref. no. RCR (06) 1). The Royal College of Radiologists, London. ISBN: 1-905034-13-X
26. Yoon HC, Goldin JG, Greaser LE 3rd et al (2000) Interscan variation in coronary artery calcium quantification in a large asymptomatic patient population. AJR Am J Roentgenol 174:803-809
27. Carr JJ, Crouse JR 3rd, Goff DC Jr et al (2000) Evaluation of subsecond gated helical CT for quantification of coronary artery calcium and comparison with electron beam CT. AJR Am J Roentgenol 174:915-921
28. O'Rourke RA, Brundage BH, Froelicher VF et al (2000) American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 102:126-140
29. Brem H, Ewend MG, Piantadosi S et al (1995) The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial. J Neurooncol 26(2):111-123
30. Karim AB, Afra D, Cornu P et al (2002) Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: An interim analysis. Int J Radiat Oncol Biol Phys 52(2):316-324
31. Cokgor I, Friedman HS, Friedman AH (1999) Chemotherapy for adults with malignant glioma. Cancer Invest 17(4):264-272
32. Cloughesy T, Selch MT, Liau L (2001) Brain. In: Haskell CM (ed) Cancer treatment, 5th edn. WB Saunders, Philadelphia, PA, pp 1106-1142
33. Kew Y, Levin VA (2003) Advances in gene therapy and immunotherapy for brain tumors. Curr Opin Neurol 16(6):665-670
34. Fecci PE, Mitchell DA, Archer GE et al (2003) The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol 64(1-2):161-176
35. Newton HB (2003) Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and RAS signaling pathways. Expert Rev Anticancer Ther 5:595-614
36. Chiocca EA, Aghi M, Fulci G (2003) Viral therapy for glioblastoma. Cancer J 3:167-179
37. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578
38. Nabors LB, Fiveash J (2005) Treatment of adults with recurrent malignant glioma. Expert Rev Neurother 5(4):509-514
39. Barentsz J, Takahashi S, Oyen W et al (2006) Commonly used imaging techniques for diagnosis and staging. J Clin Oncol 24:3234-3244
40. Rees J (2003) Advances in magnetic resonance imaging of brain tumors. Curr Opin Neurol 16:643-650
41. Lev MH, Rosen BR (1999) Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin N Am 9:309-331
42. Wong JC, Provenzale JM, Petrella JR (2000) Perfusion MR imaging of brain neoplasms. AJR Am J Roentgenol 174:1147-1157
43. Aronen HJ, Gazit IE, Louis DN et al (1994) Cerebral blood volume maps of gliomas: Comparison with tumor grade and histologic findings. Radiology 191:41-51
44. Knopp EA, Cha S, Johnson G, et al (1999) Glial neoplasms: Dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 211:791-798
45. Law M, Yang S, Wang H et al (2003) Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989-1998
46. Sugahara T, Korogi Y, Kochi M et al (1998) Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 171:1479-1486
47. Runge VM, Muroff LR, Jinkins JR (2001) Central nervous system: Review of clinical use of contrast media. Top Magn Reson Imaging 12:231-263
48. de Haen C, Cabrini M, Akhnana L et al (1999) Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 23 [Suppl 1]:S161-S168
49. Yuh WT, Fisher DJ, Engelken JD et al (1991) MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 180:485-491
50. Myhr G, Rinck PA, Borseth A (1992) Gadodiamide injection and gadopentetate dimeglumine. A double-blind study in MR imaging of the CNS. Acta Radiol 33:405-409
51. Valk J, Algra PR, Hazenberg CJ et al (1993) A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology 35:173-177
52. Balériaux D, Matos C, De Greef D (1993) Gadodiamide injection as a contrast medium for MRI of the central nervous system: A comparison with gadolinium-DOTA. Neuroradiology 35:490-494
53. Oudkerk M, Sijens PE, van Beek EJ, Kuijpers TJ (1995) Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DT-PA) in magnetic resonance imaging of the central nervous system. Invest Radiol 30:75-78
54. Greco A, Parker JR, Ratcliffe CG et al (2001) Phase III, randomized, double-blind, cross-over comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 45(4):457-463
55. Cavagna FM, Maggioni F, Castelli PM et al (1997) Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780-796
56. Pintaske J, Martiorsian P, Graf H, Erb G et al (2006) Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 41:213-221. Erratum Invest Radiol 2006, 41:859
57. Rohrer M, Bauer H, Mintorovitch J et al (2005) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 40:715-724
58. Essig, Lodermann KP, Le-Huu M et al (2006) Intraindividual compaison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5T. Invest Radiol 41:256-263
59. Rollin N, Guyotat J, Streichenberger N et al (2006) Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors. Neuroradiology 48:150-159
60. Runge VM, Parker JR, Donovan M (2002) Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol 37(5):269-280
61. Knopp MV, Runge VM, Essig M et al (2004) Primary and secondary brain tumors at MR imaging: Bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 230(1):55-64
62. Colosimo C, Knopp MV, Barreau X et al (2004) A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology 46:655-665
63. Colosimo C, Demaerel P, Tortori-Donati P et al (2005) Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children. Pediatr Radiol 35:501-510
64. Essig M, Tartaro A, Tartaglione T et al (2006) Enhancing lesions of the brain: Intraindividual crossover of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Acad Radiol 13:744-751
65. Maravilla KR, Maldjian JA, Schmalfuss IM et al (2006) Contrast enhancement of central nervous system lesions: Multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 240:389-400
66. Kuhn MJ, Picozzi P, Maldjian JA et al (2007) Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: Intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 106:557-566
67. Colosimo C, Ruscalleda J, Korves M et al (2001) Detection of intracranial metastases: A multi-center, intra-patient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dose. Invest Radiol 36:72-81
68. Seitz RJ, Wechsler W (1987) Immunohistochemical demonstration of serum proteins in human cerebral gliomas. Acta Neuropathol (Berl) 73:145-152
69. Schneider G, Kirchin MA, Pirovano G et al (2001) Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: Effect of dose on lesion detection and delineation. J Magn Reson Imaging 14(5):525-539
70. Balériaux D, Colosimo C, Ruscalleda J et al (2002) Magnetic resonance imaging of metastic disease to the brain with gadobenate dimeglumine. Neuroradiology 44:191-203
71. Ciric I, Vick NA, Mikhael MA et al (1990) Aggressive surgery for malignant supratentorial gliomas. Clin Neurosurg 36:375-383
72. Ekinci G, Akpinar IN, Baltacioglu F et al (2003) Early-postoperative magnetic resonance imaging in glial tumors: Prediction of tumor regrowth and recurrence. Eur J Radiol 45:99-107
73. Laws ER, Parney IF, Huang W, Anderson F et al (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99:467-473
74. Warmuth-Metz M (2003) Postoperative imaging after brain tumor resection. Acta Neurochir Suppl 88:13-20
75. Jolesz FA, Talos IF, Schwartz RB et al (2002) Intraoperative magnetic resonance imaging and magnetic resonance imaging-guided therapy for brain tumors. Neuroimaging Clin N Am 12:665-683
76. Nimsky C, Ganslandt O, Von Keller B et al (2004) Intraoperative high-field-strength MR imaging: Implementation and experience in 200 patients. Radiology 233:67-78
77. Ewend MG, Elbabaa S, Carey LA (2005) Current treatment paradigms for the management of patients with brain metastases. Neurosurgery 57[Suppl 5]:S66-S77
78. Kaal EC, Niel CG, Vecht CJ (2005) Therapeutic management of brain metastasis. Lancet Neurol 4:289-298
79. Kaal EC, Taphoorn MJ, Vecht CJ (2005) Symptomatic management and imaging of brain metastases. J Neurooncol 75:15-20
80. Yuh WTC, Engelken JD, Muhonen MG et al (1992) Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases. AJNR Am J Neuroradiol 13:335-345
81. Healy ME, Hesselink JR, Press GA, Middleton MS (1987) Increased detection of intracranial metastases with intravenous Gd-DTPA. Radiology 165:619-624
82. Yuh WTC, Tali ET, Nguyen HD, et al (1995) The effect of contrast dose, imaging time and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 16:373-380
83. Yuh WTC, Halloran JI, Mayr NA et al (1994) Dose of contrast material in the MR imaging evaluation of central nervous system tumors. J Magn Reson Imaging 4:242-249
84. Yuh WTC, Maley JE (1998) Contrast dosage in the neuroimaging of brain tumors. Magn Reson Imaging Clin North Am 6:113-124